FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079697357> ?p ?o ?g. }

• W2079697357 endingPage "1073" @default.
• W2079697357 startingPage "1065" @default.
• W2079697357 abstract "Aims To assess fesoterodine 8 mg efficacy over time and vs. placebo in subjects with overactive bladder (OAB) who responded suboptimally to tolterodine extended release (ER) 4 mg. Methods In a 12-week, double-blind trial, subjects with self-reported OAB symptoms for ≥ 6 months, mean of ≥ 8 micturitions and ≥ 2 to < 15 urgency urinary incontinence (UUI) episodes/24 h, and suboptimal response to tolterodine ER 4 mg (defined as ≤ 50% reduction in UUI episodes during 2-week run-in) were randomised to fesoterodine (4 mg for 1 week, 8 mg for 11 weeks) or placebo once daily. Change from baseline to week 12 in UUI episodes (primary end-point) was analysed in step-wise fashion: first, baseline vs. week 12 for fesoterodine; if significant, then change from baseline to week 12 for fesoterodine vs. placebo. Results By week 12, subjects receiving fesoterodine 8 mg had significantly greater improvement from baseline vs. placebo in UUI episodes, urgency episodes and scores on the Patient Perception of Bladder Control, Urgency Perception Scale and OAB Questionnaire Symptom Bother and Health-Related Quality of Life scales and domains (all p < 0.05). 50% and 70% UUI responder rates were also significantly higher with fesoterodine 8 mg vs. placebo at week 12 (p < 0.05). Dry mouth (placebo, 4%, 12/301; fesoterodine, 16.6%, 51/308) and constipation (placebo, 1.3%, 4/301; fesoterodine, 3.9%, 12/308) were the most frequent adverse events. Conclusions Subjects who responded suboptimally to tolterodine ER 4 mg showed significant improvements in UUI and other OAB symptoms and patient-reported outcomes, with good tolerability, during treatment with fesoterodine 8 mg vs. placebo." @default.
• W2079697357 created "2016-06-24" @default.
• W2079697357 creator A5005984728 @default.
• W2079697357 creator A5013727694 @default.
• W2079697357 creator A5028440729 @default.
• W2079697357 creator A5031776828 @default.
• W2079697357 creator A5032546357 @default.
• W2079697357 creator A5049692158 @default.
• W2079697357 creator A5072726873 @default.
• W2079697357 creator A5081214299 @default.
• W2079697357 creator A5088836842 @default.
• W2079697357 creator A5091477558 @default.
• W2079697357 date "2014-06-04" @default.
• W2079697357 modified "2023-10-01" @default.
• W2079697357 title "Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine <scp>ER</scp>" @default.
• W2079697357 cites W1495894926 @default.
• W2079697357 cites W1531562711 @default.
• W2079697357 cites W1579998465 @default.
• W2079697357 cites W1590256680 @default.
• W2079697357 cites W1834240270 @default.
• W2079697357 cites W1972477468 @default.
• W2079697357 cites W1981006688 @default.
• W2079697357 cites W1982223434 @default.
• W2079697357 cites W1985068195 @default.
• W2079697357 cites W2002743872 @default.
• W2079697357 cites W2014737244 @default.
• W2079697357 cites W2025864351 @default.
• W2079697357 cites W2028950772 @default.
• W2079697357 cites W2034782018 @default.
• W2079697357 cites W2048054700 @default.
• W2079697357 cites W2053626720 @default.
• W2079697357 cites W2054263301 @default.
• W2079697357 cites W2064365016 @default.
• W2079697357 cites W2071231390 @default.
• W2079697357 cites W2084883802 @default.
• W2079697357 cites W2089028166 @default.
• W2079697357 cites W2099381181 @default.
• W2079697357 cites W2129530182 @default.
• W2079697357 cites W2140247818 @default.
• W2079697357 cites W2149824548 @default.
• W2079697357 cites W2154340252 @default.
• W2079697357 doi "https://doi.org/10.1111/ijcp.12464" @default.
• W2079697357 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4265241" @default.
• W2079697357 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24898471" @default.
• W2079697357 hasPublicationYear "2014" @default.
• W2079697357 type Work @default.
• W2079697357 sameAs 2079697357 @default.
• W2079697357 citedByCount "22" @default.
• W2079697357 countsByYear W20796973572015 @default.
• W2079697357 countsByYear W20796973572016 @default.
• W2079697357 countsByYear W20796973572017 @default.
• W2079697357 countsByYear W20796973572018 @default.
• W2079697357 countsByYear W20796973572019 @default.
• W2079697357 countsByYear W20796973572021 @default.
• W2079697357 countsByYear W20796973572022 @default.
• W2079697357 countsByYear W20796973572023 @default.
• W2079697357 crossrefType "journal-article" @default.
• W2079697357 hasAuthorship W2079697357A5005984728 @default.
• W2079697357 hasAuthorship W2079697357A5013727694 @default.
• W2079697357 hasAuthorship W2079697357A5028440729 @default.
• W2079697357 hasAuthorship W2079697357A5031776828 @default.
• W2079697357 hasAuthorship W2079697357A5032546357 @default.
• W2079697357 hasAuthorship W2079697357A5049692158 @default.
• W2079697357 hasAuthorship W2079697357A5072726873 @default.
• W2079697357 hasAuthorship W2079697357A5081214299 @default.
• W2079697357 hasAuthorship W2079697357A5088836842 @default.
• W2079697357 hasAuthorship W2079697357A5091477558 @default.
• W2079697357 hasBestOaLocation W20796973571 @default.
• W2079697357 hasConcept C126322002 @default.
• W2079697357 hasConcept C126894567 @default.
• W2079697357 hasConcept C142724271 @default.
• W2079697357 hasConcept C159110408 @default.
• W2079697357 hasConcept C168563851 @default.
• W2079697357 hasConcept C197934379 @default.
• W2079697357 hasConcept C203092338 @default.
• W2079697357 hasConcept C204787440 @default.
• W2079697357 hasConcept C27081682 @default.
• W2079697357 hasConcept C2778531004 @default.
• W2079697357 hasConcept C2778941218 @default.
• W2079697357 hasConcept C2779951463 @default.
• W2079697357 hasConcept C2781020410 @default.
• W2079697357 hasConcept C71924100 @default.
• W2079697357 hasConceptScore W2079697357C126322002 @default.
• W2079697357 hasConceptScore W2079697357C126894567 @default.
• W2079697357 hasConceptScore W2079697357C142724271 @default.
• W2079697357 hasConceptScore W2079697357C159110408 @default.
• W2079697357 hasConceptScore W2079697357C168563851 @default.
• W2079697357 hasConceptScore W2079697357C197934379 @default.
• W2079697357 hasConceptScore W2079697357C203092338 @default.
• W2079697357 hasConceptScore W2079697357C204787440 @default.
• W2079697357 hasConceptScore W2079697357C27081682 @default.
• W2079697357 hasConceptScore W2079697357C2778531004 @default.
• W2079697357 hasConceptScore W2079697357C2778941218 @default.
• W2079697357 hasConceptScore W2079697357C2779951463 @default.
• W2079697357 hasConceptScore W2079697357C2781020410 @default.
• W2079697357 hasConceptScore W2079697357C71924100 @default.
• W2079697357 hasIssue "9" @default.
• W2079697357 hasLocation W20796973571 @default.

• next